Aptevo to Showcase Multispecific Platform at SITC 2026
Aptevo Therapeutics will present at the Society for Immunotherapy of Cancer to highlight its CD40-directed multispecific portfolio and platform technology designed to coordinate innate and adaptive immunity. This business update highlights the ce company's pipeline progress and remains relevant for investors monitoring clinical-stage immunotherapy developments.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed